This site is intended for healthcare professionals

AB Science announces a voluntary hold on the clinical studies of masitinib worldwide.

Read time: 1 mins
Last updated:3rd Jun 2021
Published:4th Jun 2021
AB Science SA announced that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide. This decision follows consultation with the French regulatory authorities (ANSM)and other regulatory agencies.
Condition: Pancreatic Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest